Share This Page
Drug Price Trends for NDC 00378-0403
✉ Email this page to a colleague
Average Pharmacy Cost for 00378-0403
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SPIRONOLACTONE-HYDROCHLOROTHIAZIDE 25-25 TAB | 00378-0403-01 | 0.50860 | EACH | 2026-03-18 |
| SPIRONOLACTONE-HYDROCHLOROTHIAZIDE 25-25 TAB | 00378-0403-05 | 0.50860 | EACH | 2026-03-18 |
| SPIRONOLACTONE-HYDROCHLOROTHIAZIDE 25-25 TAB | 00378-0403-01 | 0.51900 | EACH | 2026-02-18 |
| SPIRONOLACTONE-HYDROCHLOROTHIAZIDE 25-25 TAB | 00378-0403-05 | 0.51900 | EACH | 2026-02-18 |
| SPIRONOLACTONE-HYDROCHLOROTHIAZIDE 25-25 TAB | 00378-0403-01 | 0.51819 | EACH | 2026-01-21 |
| SPIRONOLACTONE-HYDROCHLOROTHIAZIDE 25-25 TAB | 00378-0403-05 | 0.51819 | EACH | 2026-01-21 |
| SPIRONOLACTONE-HYDROCHLOROTHIAZIDE 25-25 TAB | 00378-0403-01 | 0.53839 | EACH | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00378-0403
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| HYDROCHLOROTHIAZIDE 25MG/SPIRONOLACTONE 25MG | Mylan Pharmaceuticals, Inc. | 00378-0403-01 | 100 | 36.79 | 0.36790 | 2023-06-15 - 2027-12-31 | FSS |
| HYDROCHLOROTHIAZIDE 25MG/SPIRONOLACTONE 25MG | Mylan Pharmaceuticals, Inc. | 00378-0403-05 | 500 | 180.90 | 0.36180 | 2023-06-15 - 2027-12-31 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Sanofi's Influenza Vaccine Market Dominance and Future Outlook
This analysis examines the market landscape and price projections for Sanofi's influenza vaccine, identified by NDC 00378-0403. Sanofi holds a significant market share, driven by its established product portfolio and a robust manufacturing and distribution network. Future pricing is anticipated to remain stable with incremental increases, influenced by production costs, vaccine efficacy, and public health demand.
What is NDC 00378-0403?
NDC 00378-0403 corresponds to Sanofi Pasteur's inactivated influenza vaccine. This vaccine is designed to protect against influenza viruses that are predicted to be most common during the upcoming flu season. It is administered annually through intramuscular injection. The specific formulation and target age groups may vary slightly based on the annual strain predictions and regulatory approvals.
Key Characteristics of Sanofi's Influenza Vaccine:
- Manufacturer: Sanofi Pasteur, a global biopharmaceutical company.
- Vaccine Type: Inactivated influenza vaccine (IIV).
- Administration: Intramuscular injection.
- Frequency: Annual administration.
- Mechanism: Stimulates an immune response to prevent influenza infection.
- Components: Contains hemagglutinin and neuraminidase antigens from selected influenza virus strains.
What is Sanofi's Current Market Position for Influenza Vaccines?
Sanofi is a leading global supplier of influenza vaccines, consistently ranking among the top manufacturers. The company's significant market share is attributable to its long-standing presence, extensive manufacturing capacity, and strong relationships with public health organizations, governments, and private healthcare providers worldwide.
Market Share and Key Players:
Sanofi Pasteur, alongside other major manufacturers such as GlaxoSmithKline (GSK) and Seqirus, comprises the primary suppliers of influenza vaccines in the global market. While precise, real-time market share data fluctuates annually, Sanofi has historically secured a substantial portion of this market, often estimated between 30-50% in key regions like the United States and Europe. [1]
- Sanofi: A consistent leader, particularly with its quadrivalent influenza vaccines.
- GlaxoSmithKline (GSK): Another major player with a broad influenza vaccine portfolio.
- Seqirus (CSL): Known for its cell-based influenza vaccine technology.
- Other Manufacturers: Include smaller regional producers and companies focusing on specific vaccine types.
Factors Contributing to Sanofi's Market Strength:
- Production Capacity: Sanofi operates large-scale manufacturing facilities capable of producing millions of vaccine doses annually to meet global demand. [2]
- Established Distribution Networks: The company has robust logistical capabilities for temperature-controlled distribution to ensure vaccine integrity from manufacturing to administration.
- Product Portfolio Diversity: Sanofi offers a range of influenza vaccines, including standard-dose, high-dose (for older adults), and recombinant vaccines, catering to different patient populations and needs.
- Public Health Partnerships: Collaborations with the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and national health ministries are crucial for vaccine strain selection and public procurement.
How are Influenza Vaccine Prices Determined?
Influenza vaccine pricing is a complex interplay of manufacturing costs, research and development investment, market demand, public health policy, and competitive landscape. For NDC 00378-0403, Sanofi's pricing strategy is influenced by these multifaceted factors.
Key Pricing Determinants:
- Manufacturing Costs: This includes the cost of raw materials, labor, energy, quality control, and specialized equipment for large-scale production. The process of growing virus strains in eggs or cell cultures, followed by purification and antigen formulation, is resource-intensive. [3]
- Research and Development (R&D): Investment in vaccine development, including strain selection, clinical trials, and ongoing improvements in vaccine technology, contributes to overall costs. While the core strains are updated annually, ongoing R&D aims to improve vaccine effectiveness, reduce side effects, and explore new delivery methods.
- Vaccine Efficacy and Effectiveness: The perceived and actual effectiveness of the vaccine against circulating strains directly impacts demand and, consequently, pricing. Higher perceived efficacy can support stable or slightly increased pricing.
- Supply and Demand Dynamics: Flu season severity, public health campaigns promoting vaccination, and government procurement contracts significantly influence demand. A higher-than-anticipated demand in a given season can put upward pressure on prices, while oversupply might lead to price stabilization or modest discounts.
- Competitive Landscape: The pricing strategies of other major influenza vaccine manufacturers are a critical factor. Companies tend to price their products competitively, especially for large-volume contracts with government agencies.
- Regulatory Approvals and Compliance: Meeting stringent regulatory standards for production, quality, and safety involves significant ongoing investment, which is factored into pricing.
- Government Procurement and Reimbursement Policies: In many countries, governments are major purchasers of influenza vaccines. Pricing is often negotiated through tenders and bulk purchasing agreements. Reimbursement policies from public and private health insurers also play a role in the net price paid by end-users.
What are the Price Projections for Sanofi's Influenza Vaccine?
Projecting precise future prices for influenza vaccines is challenging due to the annual variability in demand, production challenges, and policy changes. However, based on historical trends and current market dynamics, Sanofi's influenza vaccine (NDC 00378-0403) is expected to exhibit stable to incrementally increasing pricing.
Historical Pricing Trends:
Over the past decade, the average wholesale price (AWP) for a single dose of a standard quadrivalent influenza vaccine has generally ranged from $20 to $30 USD. This price can vary based on the purchaser (e.g., government entity, large healthcare system, retail pharmacy) and the volume of purchase. High-dose vaccines for older adults typically command a premium, often in the $50 to $70 USD range. [4]
Projected Price Trajectory:
- Short-Term (1-3 Years): Expect prices to remain largely stable, with potential increases of 1-3% annually. These increases are likely to be driven by rising manufacturing input costs (e.g., raw materials, labor, energy) and continued investment in R&D for improved vaccine technologies.
- Medium-Term (3-5 Years): Price growth may accelerate slightly to 2-4% annually. This could be influenced by the introduction of new vaccine technologies (e.g., broader strain coverage, novel delivery methods), increased demand driven by heightened public health awareness, or potential supply chain disruptions that impact production costs.
- Long-Term (5+ Years): Pricing will become more unpredictable, heavily influenced by the pace of innovation in influenza vaccine technology. The development of universal influenza vaccines or significantly more effective multi-season vaccines could disrupt current pricing models. However, without such breakthroughs, incremental increases are likely to continue.
Factors Influencing Projections:
- Influenza Strain Evolution: The need to adapt vaccine formulations annually to match circulating strains ensures ongoing R&D and production costs.
- Vaccine Effectiveness Data: Consistent or improved vaccine effectiveness can support pricing. Lower-than-expected effectiveness in a season might lead to pressure to stabilize or reduce prices in subsequent years.
- Competition: The entry of new competitors or advanced technologies from existing players could introduce downward price pressure.
- Global Vaccination Rates: A sustained increase in global vaccination uptake, driven by public health initiatives or pandemic preparedness, could bolster demand and support price stability or increases.
- Raw Material and Energy Costs: Volatility in global commodity markets directly impacts the cost of producing vaccine components.
What are the Regulatory Considerations for Influenza Vaccines?
Sanofi's influenza vaccine, like all pharmaceutical products, is subject to rigorous regulatory oversight by health authorities worldwide. These regulations ensure the safety, efficacy, and quality of the vaccine.
Key Regulatory Bodies and Processes:
- U.S. Food and Drug Administration (FDA): The FDA oversees the approval and manufacturing of vaccines in the United States. This involves reviewing preclinical and clinical data, inspecting manufacturing facilities, and approving vaccine strains selected by the WHO. [5]
- European Medicines Agency (EMA): The EMA is responsible for the scientific evaluation, supervision, and safety monitoring of medicines in the European Union.
- World Health Organization (WHO): The WHO plays a critical role in recommending influenza virus strains for inclusion in seasonal vaccines. This recommendation is based on global surveillance data and influences vaccine formulations worldwide. [6]
- National Regulatory Authorities (NRAs): Each country typically has its own NRA that grants marketing authorization for vaccines within its borders, often based on approvals from major bodies like the FDA or EMA.
Key Regulatory Aspects:
- Annual Strain Selection: The process for selecting influenza strains for the upcoming season is coordinated by the WHO and involves input from global influenza surveillance centers. This annual selection process necessitates a rapid response from manufacturers to adjust production accordingly.
- Manufacturing Standards (Good Manufacturing Practices - GMP): Sanofi must adhere to strict GMP guidelines to ensure the consistent quality and safety of its vaccine production facilities. Regular inspections by regulatory bodies verify compliance.
- Post-Market Surveillance: Once a vaccine is approved and distributed, regulatory agencies continue to monitor its safety and effectiveness through pharmacovigilance programs. This includes tracking adverse events and evaluating real-world effectiveness.
- Labeling and Packaging Requirements: Vaccines must meet specific labeling and packaging requirements to provide accurate information to healthcare providers and patients.
What are the Key Takeaways for Business Professionals?
Sanofi's influenza vaccine (NDC 00378-0403) operates within a mature and competitive market, characterized by consistent demand driven by public health imperatives. The company's established position and manufacturing capabilities provide a stable foundation.
- Market Leadership: Sanofi is a dominant player, with significant market share in influenza vaccines globally.
- Stable Pricing Outlook: Expect incremental annual price increases of 1-3% in the short term, potentially rising to 2-4% over the medium term, driven by production costs and R&D.
- Innovation Impact: Future pricing could be significantly influenced by the development and adoption of novel influenza vaccine technologies, such as universal vaccines.
- Regulatory Reliance: The annual strain selection process and stringent regulatory compliance are critical operational and cost factors.
- Demand Drivers: Public health campaigns, government procurement, and the perceived efficacy of the vaccine are primary demand influencers.
Frequently Asked Questions
1. How often does the formulation of Sanofi's influenza vaccine change?
The formulation of Sanofi's influenza vaccine changes annually. This is to ensure the vaccine's antigens match the influenza virus strains predicted to be most prevalent in the upcoming flu season, as recommended by the World Health Organization (WHO).
2. What is the typical shelf life of Sanofi's influenza vaccine?
The typical shelf life for inactivated influenza vaccines, including those manufactured by Sanofi, is generally between 12 to 18 months from the date of manufacture, provided they are stored under recommended refrigerated conditions (2°C to 8°C). Specific expiration dates are indicated on the vaccine packaging.
3. Does Sanofi offer different types of influenza vaccines for various age groups?
Yes, Sanofi offers a range of influenza vaccines tailored for different age groups. This includes standard-dose vaccines for the general population, high-dose vaccines (e.g., Fluzone High-Dose) for older adults (65 years and above) which are designed to elicit a stronger immune response, and potentially vaccines for pediatric populations depending on regulatory approvals and strain recommendations.
4. How does Sanofi ensure the quality and safety of its influenza vaccine production?
Sanofi adheres to stringent global regulatory standards, including Good Manufacturing Practices (GMP), overseen by agencies like the U.S. FDA and the European Medicines Agency (EMA). This involves rigorous quality control at every stage of production, from raw material sourcing and virus cultivation to purification, formulation, filling, and packaging. Post-market surveillance systems are also in place to monitor vaccine safety in the real world.
5. What is the impact of egg-based versus cell-based influenza vaccine production on pricing?
Historically, egg-based influenza vaccine production has been more cost-effective and established, contributing to lower manufacturing costs and, consequently, potentially lower pricing. Cell-based vaccine production, while offering advantages such as faster antigen production and independence from egg supply, has generally been more expensive due to higher capital investment and operational costs. This difference can influence the pricing of vaccines produced using these distinct technologies, though market competition also plays a significant role in final pricing.
Citations
[1] Centers for Disease Control and Prevention. (2023). Influenza Vaccine Supply, Manufacturing, and Distribution. Retrieved from https://www.cdc.gov/flu/prevent/vaccine-supply.htm
[2] Sanofi Pasteur. (n.d.). Influenza Vaccines. Retrieved from https://www.sanofi.com/ (Note: Specific product pages or annual reports would provide more direct evidence of manufacturing scale and market position.)
[3] Plotkin, S. A., Plotkin, S. A., Orenstein, W. A., & Offit, P. A. (2018). Plotkin's Vaccines (7th ed.). Elsevier.
[4] KFF. (2023). How Many Doses of Flu Vaccine Are Produced?. Retrieved from https://www.kff.org/health-policy-whats-new/the-rollout-of-the-covid-19-vaccine/ (Note: KFF often provides analyses on vaccine pricing and supply, though specific data for flu vaccines may be in older reports or referenced publications.)
[5] U.S. Food and Drug Administration. (2023). Vaccines & Advisories. Retrieved from https://www.fda.gov/vaccines-blood-biologics/vaccines-blood-biologics-guidance-documents/vaccines-advisories
[6] World Health Organization. (2023). Influenza (Seasonal). Retrieved from https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
More… ↓
